Gliesse Pharmaceuticals Private limited works on a unique business model. We work on exclusivity basis with many large pharmaceutical CMO and OEMs of India, our unique business model is attributed to 3 major pillars: 1. Our Own Branded Generic Formulations in Emerging, Semi & Non Regulated Markets 2. BULK Drugs - API & Intermediates exports 3. Generic Finished Formulation on exclusivity agreements for MNCs and Global Pharmaceutical companies on cost efficient model. We work on an asset and Capex Light model by engaging into Exclusive Agreements with our local API/Intermediate & Finished Dosage Formulation CMO partners. Our strength lies in our sourcing and we can be a one stop solution for all Pharmaceutical requirements from new development to commercialisation. Our formulation tie ups include WHO GMP, USFDA, EUGMP, UKMHRA, PMDA, TGA, PICS and Health Canada approved sites. Over the next decade we plan to get a wide range of our own brand name product approvals across diverse geographies covering major Chronic therapeutic segments, with branding focus majorly on emerging markets.
